Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
We assessed the safety and immunogenicity of prime-boost vectors encoding the Plasmodium falciparum circumsporozoite (CS) protein expressed either in the attenuated fowl-pox virus (FP9) or modified vaccinia virus Ankara (MVA). Thirty-two adult Gambians in groups of four to eight received one, two or three doses of FP9 CS and/or MVA CS. No serious adverse event was observed following vaccination. The most immunogenic regimen was two doses of FP9 followed by a single dose of MVA 4 weeks later (an average of 1000 IFN-gamma spot forming units/million PBMCs). This level of effector T-cell responses appears higher than that seen in previously reported studies of CS-based candidate malaria vaccines.
Imoukhuede
E B
EB
MRC Laboratories, Banjul, Gambia. ebimoukhuede@hotmail.co.uk
Berthoud
T
T
Milligan
P
P
Bojang
K
K
Ismaili
J
J
Keating
S
S
Nwakanma
D
D
Keita
S
S
Njie
F
F
Sowe
M
M
Todryk
S
S
Laidlaw
S M
SM
Skinner
M A
MA
Lang
T
T
Gilbert
S
S
Greenwood
B M
BM
Hill
A V S
AV
D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis*; D000918:Antibody Specificity; D003429:Cross Reactions; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D005714:Gambia; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000032:analysis / Q000096:biosynthesis; D007371:Interferon-gamma; D017780:Malaria Vaccines / Q000009:adverse effects* / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control; D008297:Male; D010641:Phenotype; D010963:Plasmodium falciparum / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D000913:Antibodies, Protozoan; D007074:Immunoglobulin G; D017780:Malaria Vaccines; D007371:Interferon-gamma